Predicting treatment response more accurately

The HI virus is feared, not least, because of its great adaptability. If the virus mutates at precisely the point targeted by a drug, it is able to neutralise the attack and the treatment fails. To minimise these viral defence mechanisms, doctors treat patients with modern combination therapies involving the simultaneous administration of several drugs. This approach forces the virus to run through a series of mutations before it becomes immune to the drugs.

Sequential nature of mutations

"It is not easy to decide which of the over 30 combination therapies is best suited to a patient," says Huldrych Günthard from Zurich University Hospital, president of the Swiss HIV Cohort Study. The decision is based on the prospects of success and therefore on the genetic make-up of a particular . The established already consider the genetics of the virus but they neglect that the virus continuously evolves through sequential .

Choosing the right therapy for each patient

In cooperation with the Swiss HIV Cohort Study, Niko Beerenwinkel and his team from ETH Zurich have now developed a more accurate prediction model based on a probabilistic method*. This model calculates the possible evolutionary paths of the virus and yields a new predictive measure for the development of resistances: the so-called individualised genetic barrier. When applied retrospectively to 2185 patients of the HIV Cohort, the new approach made it possible to predict more accurately compared to the existing models. "We are now introducing the individualised genetic barrier in a and hope that it will help us in the future to identify the best therapy for each patient," says Günthard.

The Swiss HIV Cohort Study

Established in 1988, the Cohort Study aims to generate knowledge about HIV infection and AIDS as well as to improve the care given to patients. All Swiss hospitals specialising in HIV (Basel, Berne, Geneva, Lausanne, Lugano, St. Gallen and Zurich) have collected and analysed data from over 18,000 HIV-positive persons. More than 8,800 persons are currently taking part in the Swiss HIV Cohort Study. Almost a third of them are women.

www.shcs.ch

More information: * Niko Beerenwinkel, Hesam Montazeri, Heike Schuhmacher, Patrick Knupfer, Viktor von Wyl, Hansjakob Furrer, Manuel Battegay, Bernard Hirschel, Matthias Cavassini, Pietro Vernazza, Enos Bernasconi, Sabine Yerly, Jürg Böni, Thomas Klimkait, Cristina Cellerai, Huldrych F. Günthard, and the Swiss HIV Cohort Study (2013). The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology online. DOI: 10.1371/journal.pcbi.1003203

Provided by Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Caution still advised despite ever-improving HIV drugs

Nov 30, 2012

Combination therapies for AIDS are becoming increasingly effective, but they cannot protect against other sexually transmitted illnesses. It is unsafe for patients taking antiretroviral drugs to stop using ...

Platelets block HIV

Jul 23, 2013

Scientists of the DPZ have shown that platelet activation inhibits the host cell entry of HIV

Recommended for you

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments